US Stock MarketDetailed Quotes

ACIU AC Immune

Watchlist
  • 3.360
  • -0.040-1.18%
Close Nov 27 16:00 ET
  • 3.360
  • 0.0000.00%
Post 16:00 ET
332.45MMarket Cap-7400P/E (TTM)
Full Hours
  • 5D
  • Daily
  • Weekly
  • Monthly
  • 1Q
  • 1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Comments

    Trytosaveabit
    Trytosaveabit
    Nov 14 06:03
    Update
    $AC Immune (ACIU.US)$ Reuters· 2 mins ago
    AC Immune Reports Positive Interim Results From Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease
    Jaguar8
    Jaguar8
    Nov 14 06:02
    NEWS
    $AC Immune (ACIU.US)$
    AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease
    AC Immune (NASDAQ: ACIU) announced positive interim results from its Phase 2 VacSYn trial of ACI-7104.056, an active immunotherapy for early Parkinson's disease.
    The treatment showed significant efficacy, inducing anti-a-synuclein antibody levels 16-fold higherthan placebo after 3 immunizations, with a 100% patient response rate.
    The trial rep...
    amiable Hedgehog_758
    amiable Hedgehog_758
    Sep 17 06:34
    $AC Immune (ACIU.US)$
    AC Immune Reaches Key Milestone in Alzheimer's Immunotherapy, Receives CHF 24.6M
    Benzinga· 10 mins ago5mins
    AC Immune (ACIU.US)
    3.270
    3.530
    +2.83%
    +7.95%
    AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced that it will receive the second ReTain-related milestone payment (CHF 24.6 million) under its agreement with Janssen Pharmaceuticals, Inc. (Janssen), a Johnson & Johnson co...
    Trytosaveabit
    Trytosaveabit
    Sep 17 06:09
    News
    $AC Immune (ACIU.US)$ Press Release: AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer's Disease
    Dow Jones· 7 mins ago
    AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer's Disease
    AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer's Disease
    1
    Jaguar8
    Jaguar8
    Sep 17 06:02
    NEWS
    $AC Immune (ACIU.US)$
    AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer’s Disease
    AC Immune SA (NASDAQ: ACIU) has received a second milestone payment of CHF 24.6 million from Janssen Pharmaceuticals for the rapid prescreening rate in the Phase 2b ReTain trial of ACI-35.030 (JNJ-2056) for preclinical Alzheimer's disease. This brings the total milestone payments for this trial to CHF 40 million. The potentially regist...
Read more

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg

No Data